To the full analysis
Sarepta Therapeutics stock: growth
SRPTSarepta Therapeutics reported $2.2B in revenue for fiscal 2025, up 15.6% on the prior year, up 32.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
68%
per year from 2006 to 2025, per share 47.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 32.4% | 111.1% | 68.0% |
| Revenue per share | 24.8% | 92.8% | 47.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $115.29K | −$31.07M | −$22.07M |
| 2007 | $10.99M | −$27.17M | −$26.8M |
| 2008 | $21.26M | −$23.95M | −$13.56M |
| 2009 | $17.59M | −$25.16M | −$10.79M |
| 2010 | $29.42M | −$32.18M | −$17.16M |
| 2011 | $46.99M | −$2.32M | −$25.98M |
| 2012 | $37.33M | −$121.29M | −$30.84M |
| 2013 | $14.22M | −$111.99M | −$68.47M |
| 2014 | $9.76M | −$135.79M | −$155.36M |
| 2015 | $1.25M | −$220.03M | −$154.3M |
| 2016 | $5.42M | −$267.27M | −$252.69M |
| 2017 | $154.58M | −$50.69M | −$253.21M |
| 2018 | $301.03M | −$361.92M | −$453.01M |
| 2019 | $380.83M | −$715.08M | −$516.09M |
| 2020 | $540.1M | −$554.13M | $25.26M |
| 2021 | $701.89M | −$418.78M | −$481.66M |
| 2022 | $933.01M | −$703.49M | −$357.6M |
| 2023 | $1.24B | −$535.98M | −$588.34M |
| 2024 | $1.9B | $235.24M | −$352.74M |
| 2025 | $2.2B | −$713.41M | −$307.45M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 9 May 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.